---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010211"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:29:05.491342+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma raises $5.75M in public offering, regains Nasdaq equity compliance

## Summary
- Closed underwritten offering of 1.34M shares and 17.8M pre-funded warrants at $0.30/share, net proceeds ~$5.2M.
- Net proceeds to fund Phase II trial of Ropidoxuridine, $2.8M to CRO Theradex, plus up to $2.0M for marketing.
- Believes it has regained compliance with Nasdaq minimum stockholders' equity rule of $2.5M after offering.
- Offering was sole-underwritten by WestPark Capital; closed March 13, 2025.
- Previously received Nasdaq deficiency notice on Sep 10, 2024; plan accepted Nov 26, 2024.

## SEC filing metadata
- accession: 0001493152-25-010211
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225010211/0001493152-25-010211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225010211/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010211
- JSON: https://secwatch.observer/filing/0001493152-25-010211.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.